Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 6.2% – Here’s What Happened

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price traded up 6.2% during mid-day trading on Monday. The company traded as high as $47.61 and last traded at $47.1770. 139,102 shares were traded during mid-day trading, a decline of 64% from the average session volume of 390,397 shares. The stock had previously closed at $44.43.

Analyst Ratings Changes

Several research firms recently commented on PLSE. Mizuho set a $55.00 price objective on shares of Pulse Biosciences in a research note on Tuesday, October 13th. BTIG Research began coverage on shares of Pulse Biosciences in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, October 15th. Oppenheimer lifted their price target on shares of Pulse Biosciences from $35.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, October 13th. Finally, Freedom Capital raised Pulse Biosciences to a “strong-buy” rating in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.20.

Pulse Biosciences Stock Performance

The firm’s 50-day simple moving average is $50.07 and its two-hundred day simple moving average is $34.81.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. As a group, equities analysts expect that Pulse Biosciences, Inc will post -1.34 earnings per share for the current year.

Insider Buying and Selling at Pulse Biosciences

In other news, COO Liane Teplitsky bought 1,001 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were purchased at an average cost of $49.95 per share, with a total value of $49,999.95. Following the transaction, the chief operating officer directly owned 4,095 shares in the company, valued at approximately $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired 4,095 shares of company stock worth $199,931 over the last 90 days. 74.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLSE. Osterweis Capital Management Inc. acquired a new position in shares of Pulse Biosciences in the second quarter valued at about $28,000. Jupiter Topco LLC purchased a new position in shares of Pulse Biosciences in the second quarter worth about $241,000. GSA Capital Partners LLP acquired a new stake in shares of Pulse Biosciences during the second quarter worth about $290,000. Legal & General Group Plc acquired a new stake in shares of Pulse Biosciences during the second quarter worth about $395,000. Finally, Cetera Investment Advisers acquired a new stake in shares of Pulse Biosciences during the first quarter worth about $387,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.